{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:24:40Z","timestamp":1793813080274,"version":"4.6.1"},"reference-count":179,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015640","name":"Tongji Hospital","doi-asserted-by":"publisher","award":["2024TJCR008"],"award-info":[{"award-number":["2024TJCR008"]}],"id":[{"id":"10.13039\/501100015640","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015640","name":"Tongji Hospital","doi-asserted-by":"publisher","award":["2019CR206"],"award-info":[{"award-number":["2019CR206"]}],"id":[{"id":"10.13039\/501100015640","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32450786"],"award-info":[{"award-number":["32450786"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271847"],"award-info":[{"award-number":["82271847"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32400583"],"award-info":[{"award-number":["32400583"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.autrev.2026.104042","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:42:34Z","timestamp":1774543354000},"page":"104042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The BAFF\/APRIL system at the crossroads of B cell memory and autoimmune relapse: Implication into the therapeutic strategies"],"prefix":"10.1016","volume":"25","author":[{"given":"Chengqian","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaozhe","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2026.104042_bb0005","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1074-7613(04)00112-8","article-title":"Pathogenic roles of B cells in human autoimmunity; insights from the clinic","volume":"20","author":"Martin","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2026.104042_bb0010","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41584-019-0211-0","article-title":"B cell checkpoints in autoimmune rheumatic diseases","volume":"15","author":"Rubin","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2026.104042_bb0015","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/imr.12821","article-title":"Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies","volume":"292","author":"Meffre","year":"2019","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2026.104042_bb0020","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","article-title":"Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases","volume":"64","author":"Gottenberg","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104042_bb0025","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","article-title":"Rituximab for IgG4-related disease: a prospective, open-label trial","volume":"74","author":"Carruthers","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104042_bb0030","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104042_bb0035","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10570-023-05645-3","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2026.104042_bb0040","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104042_bb0045","article-title":"Mechanisms of B cell tolerance in health and autoimmunity","author":"Ponnan","year":"2025","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104042_bb0050","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1196\/annals.1358.014","article-title":"Human B cell tolerance and its failure in rheumatoid arthritis","volume":"1062","author":"Samuels","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2026.104042_bb0055","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.coi.2019.09.005","article-title":"Pathogenic memory plasma cells in autoimmunity","volume":"61","author":"Chang","year":"2019","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0060","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s13075-018-1718-5","article-title":"Increase of circulating memory B cells after glucocorticoid-induced remission identifies patients at risk of IgG4-related disease relapse","volume":"20","author":"Lanzillotta","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104042_bb0065","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-lived plasma cells are contained within the CD19\u2212CD38hiCD138+ subset in human bone marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2026.104042_bb0070","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104042_bb0075","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1136\/ard-2022-223529","article-title":"BLyS\/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept","volume":"82","author":"Cai","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104042_bb0080","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104042_bb0085","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","article-title":"BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells","volume":"31","author":"M\u00fcller","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2026.104042_bb0090","article-title":"BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis","volume":"S000349672504186X","author":"Hu","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104042_bb0095","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1038\/s41591-025-03937-8","article-title":"Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial","volume":"31","author":"Feng","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2026.104042_bb0100","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104042_bb0105","first-page":"188","article-title":"Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis","author":"Qin","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2026.104042_bb0110","doi-asserted-by":"crossref","first-page":"e834","DOI":"10.1016\/S2665-9913(25)00215-2","article-title":"Anti-BCMA CAR-T for the treatment of IgG4-related disease: clinical assessment and single-cell transcriptomic analysis","volume":"7","author":"Cai","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2026.104042_bb0115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature01543","article-title":"Ligand\u2013receptor binding revealed by the TNF family member TALL-1","volume":"423","author":"Liu","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2026.104042_bb0120","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.autrev.2026.104042_bb0125","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1359-6101(03)00023-6","article-title":"The TNF family members BAFF and APRIL: the growing complexity","volume":"14","author":"Mackay","year":"2003","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.autrev.2026.104042_bb0130","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nri2572","article-title":"Cracking the BAFF code","volume":"9","author":"Mackay","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0135","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1126\/science.1061964","article-title":"An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway","volume":"293","author":"Schiemann","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.autrev.2026.104042_bb0140","series-title":"A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;pl3) translocation in a malignant T cell lymphoma","author":"Carbonnel","year":"2026"},{"key":"10.1016\/j.autrev.2026.104042_bb0145","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2026.104042_bb0150","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.4049\/jimmunol.179.11.7276","article-title":"Regulated expression of BAFF-binding receptors during human B cell differentiation","volume":"179","author":"Darce","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0155","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0960-9822(00)00566-2","article-title":"Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI","volume":"10","author":"Marsters","year":"2000","journal-title":"Curr Biol"},{"key":"10.1016\/j.autrev.2026.104042_bb0160","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jaci.2013.01.046","article-title":"B-cell biology and development","volume":"131","author":"Pieper","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0165","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1146\/annurev.immunol.23.021704.115732","article-title":"Antigen-specific memory B cell development","volume":"23","author":"McHeyzer-Williams","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0170","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2404309121","article-title":"Unique and redundant roles of mouse BCMA, TACI, BAFF, APRIL, and IL-6 in supporting antibody-producing cells in different tissues","volume":"121","author":"Eslami","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2026.104042_bb0175","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.4049\/jimmunol.1001931","article-title":"B cell maturation antigen deficiency exacerbates lymphoproliferation and autoimmunity in murine lupus","volume":"186","author":"Jiang","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0180","doi-asserted-by":"crossref","first-page":"7106","DOI":"10.1038\/s41467-025-62530-2","article-title":"B cell maturation antigen (BCMA) is dispensable for the survival of long-lived plasma cells","volume":"16","author":"Menzel","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2026.104042_bb0185","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cytogfr.2021.11.004","article-title":"B cell-activating factor and its targeted therapy in autoimmune diseases","volume":"64","author":"Zhang","year":"2022","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.autrev.2026.104042_bb0190","doi-asserted-by":"crossref","first-page":"762","DOI":"10.4049\/jimmunol.172.2.762","article-title":"Cutting edge: BAFF regulates CD21\/35 and CD23 expression independent of its B cell survival function","volume":"172","author":"Gorelik","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0195","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.4049\/jimmunol.178.5.2872","article-title":"IL-21 and BAFF\/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells","volume":"178","author":"Ettinger","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0200","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.immuni.2004.05.010","article-title":"Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches","volume":"20","author":"Thien","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2026.104042_bb0205","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jaci.2020.03.025","article-title":"APRIL-dependent lifelong plasmacyte maintenance and immunoglobulin production in humans","volume":"146","author":"Yeh","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0210","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/79802","article-title":"APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity","volume":"1","author":"Yu","year":"2000","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0215","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1084\/jem.20032000","article-title":"TACI and BAFF-R mediate isotype switching in B cells","volume":"201","author":"Castigli","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2026.104042_bb0220","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.183400","article-title":"BAFF promotes follicular helper T cell development and germinal center formation through BR3 signal","volume":"9","author":"Chen","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.autrev.2026.104042_bb0225","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/art.38950","article-title":"BAFF regulates follicular helper t cells and affects their accumulation and interferon-\u03b3 production in autoimmunity","volume":"67","author":"Coquery","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104042_bb0230","article-title":"BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis","volume":"6","author":"Zhou","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2026.104042_bb0235","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cytogfr.2013.12.011","article-title":"The function of BAFF on T helper cells in autoimmunity","volume":"25","author":"Chen","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.autrev.2026.104042_bb0240","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/ni842","article-title":"BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells","volume":"3","author":"Claudio","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0245","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.cyto.2015.07.014","article-title":"The role of BAFF in the progression of rheumatoid arthritis","volume":"76","author":"Wei","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.autrev.2026.104042_bb0250","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.autrev.2004.02.001","article-title":"BLyS--an essential survival factor for B cells: basic biology, links to pathology and therapeutic target","volume":"3","author":"Baker","year":"2004","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104042_bb0255","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.3389\/fimmu.2018.02285","article-title":"BAFF and BAFF-receptor in B cell selection and survival","volume":"9","author":"Smulski","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103133","article-title":"Targeting NF-\u03baB signaling in B cells as a potential new treatment modality for ANCA-associated vasculitis","volume":"142","author":"Merino-Vico","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104042_bb0265","doi-asserted-by":"crossref","first-page":"5360","DOI":"10.1038\/ncomms6360","article-title":"Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity","volume":"5","author":"Willmann","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2026.104042_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111019","article-title":"BAFFR activates PI3K\/AKT signaling in human naive but not in switched memory B cells through direct interactions with B cell antigen receptors","volume":"39","author":"Sevdali","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.autrev.2026.104042_bb0275","series-title":"Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF- B activation pathways","author":"Zarnegar","year":"2026"},{"key":"10.1016\/j.autrev.2026.104042_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2025.100288","article-title":"The role of soluble CD40L in autoimmune diseases","volume":"10","author":"Mabrouk","year":"2025","journal-title":"J Transl Autoimmunity"},{"key":"10.1016\/j.autrev.2026.104042_bb0285","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","article-title":"Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond","volume":"141","author":"Karnell","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.autrev.2026.104042_bb0290","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/08916930400002386","article-title":"The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway","volume":"37","author":"Toubi","year":"2004","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2026.104042_bb0295","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/ajt.12984","article-title":"B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) mediate CD40-independent help by memory CD4 T cells","volume":"15","author":"Gorbacheva","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.autrev.2026.104042_bb0300","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/ni829","article-title":"DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL","volume":"3","author":"Litinskiy","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0305","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1172\/JCI18025","article-title":"BAFF selectively enhances the survival of plasmablasts generated from human memory B cells","volume":"112","author":"Avery","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2026.104042_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107337","article-title":"Different regulatory effects of CD40 ligand and B-cell activating factor on the function of B cells","volume":"91","author":"Guo","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2026.104042_bb0315","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3389\/fimmu.2017.01791","article-title":"The CD40\u2013CD40L dyad in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"8","author":"Aarts","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0320","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/annrheumdis-2018-214729","article-title":"Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study","volume":"78","author":"Visvanathan","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104042_bb0325","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/72162","article-title":"Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand","volume":"6","author":"Kawai","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2026.104042_bb0330","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nri1886","article-title":"Competence and competition: the challenge of becoming a long-lived plasma cell","volume":"6","author":"Radbruch","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0335","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/s41467-017-01901-w","article-title":"Plasma cell survival in the absence of B cell memory","volume":"8","author":"Hammarlund","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2026.104042_bb0340","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41577-019-0244-2","article-title":"B cell memory: building two walls of protection against pathogens","volume":"20","author":"Akkaya","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0345","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191167","article-title":"BAFFR controls early memory B cell responses but is dispensable for germinal center function","volume":"218","author":"Lau","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2026.104042_bb0350","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191393","article-title":"Critical requirement for BCR, BAFF, and BAFFR in memory B cell survival","volume":"218","author":"M\u00fcller-Winkler","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2026.104042_bb0355","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/imr.13016","article-title":"Memory B cells and plasma cells: the differentiative continuum of humoral immunity","volume":"303","author":"Cancro","year":"2021","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2026.104042_bb0360","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41577-023-00897-3","article-title":"Memory B cells","volume":"24","author":"Inoue","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0365","doi-asserted-by":"crossref","first-page":"15401","DOI":"10.1073\/pnas.1200386109","article-title":"Deficiency in TNFRSF13B (TACI) expands T-follicular helper and germinal center B cells via increased ICOS-ligand expression but impairs plasma cell survival","volume":"109","author":"Ou","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2026.104042_bb0370","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.it.2012.07.005","article-title":"Heterogeneity in the differentiation and function of memory B cells","volume":"33","author":"Taylor","year":"2012","journal-title":"Trends Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0375","series-title":"Do memory B cells form secondary germinal Centers? It depends","first-page":"10","author":"Pape","year":"2018"},{"key":"10.1016\/j.autrev.2026.104042_bb0380","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","article-title":"BAFF, APRIL and their receptors: structure, function and signaling","volume":"18","author":"Bossen","year":"2006","journal-title":"Semin Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0385","first-page":"25","article-title":"B-cell maturation antigen (BCMA) as a biomarker and potential treatment target in systemic lupus erythematosus","author":"Martin","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2026.104042_bb0390","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/ar3433","article-title":"Mechanisms of B cell autoimmunity in SLE","volume":"13","author":"D\u00f6rner","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104042_bb0395","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1235937","article-title":"BAFF system expression in double negative 2, activated na\u00efve and activated memory B cells in systemic lupus erythematosus","volume":"14","author":"\u00c1lvarez G\u00f3mez","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0400","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s11658-025-00749-z","article-title":"Immune cell aberrations in systemic lupus erythematosus: navigating the targeted therapies toward precision management","volume":"30","author":"Wu","year":"2025","journal-title":"Cell Mol Biol Lett"},{"key":"10.1016\/j.autrev.2026.104042_bb0405","first-page":"220","article-title":"Age-associated B cells are heterogeneous and dynamic drivers of autoimmunity in mice","author":"Nickerson","year":"2023","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2026.104042_bb0410","doi-asserted-by":"crossref","DOI":"10.55563\/clinexprheumatol\/1b9d13","article-title":"Expansion and surface makers of age-associated B cells in IgG4-related disease","author":"Zhang","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2026.104042_bb0415","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2026.104042_bb0420","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.1038\/s41598-020-63390-0","article-title":"Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients","volume":"10","author":"Salazar-Camarena","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2026.104042_bb0425","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41584-024-01179-5","article-title":"The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus","volume":"20","author":"D\u00f6rner","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2026.104042_bb0430","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.40358","article-title":"Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled","volume":"70","author":"Gordon","year":"2018","journal-title":"Pilot Trial Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104042_bb0435","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sj\u00f6gren\u2019s syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104042_bb0440","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/rheumatology\/kead281","article-title":"Belimumab treatment of adult idiopathic inflammatory myopathy","volume":"63","author":"Marder","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104042_bb0445","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/rheumatology\/keae286","article-title":"Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus","volume":"63","author":"Arends","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2026.104042_bb0450","first-page":"11","article-title":"Belimumab decreases autophagy and citrullination in peripheral blood mononuclear cells from patients with systemic lupus erythematosus","author":"Colasanti","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.autrev.2026.104042_bb0455","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/rheumatology\/kead265","article-title":"Efficacy and safety of telitacicept in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"63","author":"Xu","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2026.104042_bb0460","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.70174","article-title":"Case series: effectiveness and safety of Telitacicept in Chinese patients with primary Sj\u00f6gren\u2019s disease","volume":"28","author":"Wu","year":"2025","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104042_bb0465","article-title":"Case report: a refractory unusual tetrad of overlap syndrome involving rheumatoid arthritis, Sj\u00f6gren\u2019s syndrome, autoimmune hepatitis, and type 1 renal tubular acidosis, successfully treated with a BLyS\/APRIL dual inhibitor","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0470","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/09612033241233021","article-title":"Refractory lupus hepatitis successfully treated with telitacicept who failed to belimumab: a case report and literature review","volume":"33","author":"Fan","year":"2024","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2026.104042_bb0475","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell\u2013engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104042_bb0480","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.ard.2025.05.007","article-title":"One-year remission of therapy-resistant SLE after a single course with the bispecific CD3: BCMA antibody teclistamab, but induction of a non-infectious Crohn\u2019s-like inflammatory bowel disease","volume":"84","author":"Lorenz","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104042_bb0485","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc2407150","article-title":"Teclistamab-induced remission in refractory systemic lupus erythematosus","volume":"391","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104042_bb0490","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cpt.2929","article-title":"Pharmacokinetics and pharmacokinetic\/pharmacodynamic properties of Rozibafusp alfa, a bispecific inhibitor of BAFF and ICOSL: analyses of phase I clinical trials","volume":"114","author":"Abuqayyas","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.autrev.2026.104042_bb0495","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/acr2.11487","volume":"vol. 4","author":"Abuqayyas","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.autrev.2026.104042_bb0500","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104042_bb0505","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/annrheumdis-2015-207653","article-title":"Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study","volume":"75","author":"Isenberg","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104042_bb0510","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/annrheumdis-2018-213032","article-title":"Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial","volume":"77","author":"Merrill","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104042_bb0515","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","article-title":"Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"13","author":"Kappos","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2026.104042_bb0520","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)","volume":"74","author":"Isenberg","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104042_bb0525","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/ene.14105","article-title":"Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis","volume":"27","author":"Baker","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2026.104042_bb0530","doi-asserted-by":"crossref","DOI":"10.1172\/JCI33760","article-title":"APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa","author":"Huard","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2026.104042_bb0535","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/mi.2013.64","article-title":"Limited expression of APRIL and its receptors prior to intestinal IgA plasma cell development during human infancy","volume":"7","author":"Gustafson","year":"2014","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0540","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3389\/fimmu.2019.01368","article-title":"APRIL induces a novel subset of IgA+ regulatory B cells that suppress inflammation via expression of IL-10 and PD-L1","volume":"10","author":"Fehres","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0545","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.amjms.2022.05.008","article-title":"B-cell activating factor and a proliferation-inducing ligand in relation to intima-media thickness as biomarkers of premature atherosclerosis in systemic lupus erythematosus patients","volume":"364","author":"Shater","year":"2022","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.autrev.2026.104042_bb0550","first-page":"1256","article-title":"Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis","volume":"35","author":"Bosello","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104042_bb0555","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3899\/jrheum.121110","article-title":"BAFF and TACI gene expression are increased in patients with untreated very early rheumatoid arthritis","volume":"40","author":"Moura","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104042_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109870","article-title":"B cell activating factor levels are linked to distinct B cell markers in multiple sclerosis and following B cell depletion and repopulation","volume":"258","author":"Asplund H\u00f6gelin","year":"2024","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0565","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jneuroim.2003.10.056","article-title":"Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis","volume":"148","author":"Magliozzi","year":"2004","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0570","doi-asserted-by":"crossref","first-page":"eadi0295","DOI":"10.1126\/scitranslmed.adi0295","article-title":"B cell depletion with anti-CD20 promotes neuroprotection in a BAFF-dependent manner in mice and humans","volume":"16","author":"Wang","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2026.104042_bb0575","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1084\/jem.20041674","article-title":"BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma","volume":"201","author":"Krumbholz","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2026.104042_bb0580","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/art.42462","article-title":"Povetacicept, an enhanced dual APRIL\/BAFF antagonist that modulates B lymphocytes and pathogenic autoantibodies for the treatment of lupus and other B cell-related autoimmune diseases","volume":"75","author":"Evans","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104042_bb0585","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41392-019-0051-z","article-title":"Therapeutic effects of a novel BAFF blocker on arthritis","volume":"4","author":"Zhou","year":"2019","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.autrev.2026.104042_bb0590","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2026.104042_bb0595","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104042_bb0600","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1016\/j.ymthe.2024.12.018","article-title":"Targeting human plasma cells using regulated BCMA CAR T cells eliminates circulating antibodies in humanized mice","volume":"33","author":"Honaker","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.autrev.2026.104042_bb0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2025.103369","article-title":"CAR-T cell targeting three receptors on autoreactive B cells for systemic lupus erythematosus therapy","volume":"151","author":"Uppin","year":"2025","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104042_bb0610","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1016\/j.cell.2025.05.038","article-title":"An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis","volume":"188","author":"Wang","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2026.104042_bb0615","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood.2023023557","article-title":"Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma","volume":"144","author":"Firestone","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2026.104042_bb0620","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.jaci.2024.12.1066","article-title":"Chimeric antigen receptor-modified T-cell therapy: recent updates and challenges in autoimmune diseases","volume":"155","author":"Ca\u00ebl","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0625","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jep.2016.05.034","article-title":"CP-25 attenuates the inflammatory response of fibroblast-like synoviocytes co-cultured with BAFF-activated CD4(+) T cells","volume":"189","author":"Jia","year":"2016","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.autrev.2026.104042_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.140057","article-title":"Development and therapeutic assessment of bispecific nanobodies targeting B-cell activating factor and interleukin-17 for the neutralization of inflammatory mediators in autoimmune diseases","volume":"305","author":"Xin","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.autrev.2026.104042_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113886","article-title":"Genetically engineered extracellular vesicles expressing decoy protein TACI provide a therapeutic effect in systemic lupus erythematosus mouse model","volume":"384","author":"Cai","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.autrev.2026.104042_bb0640","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","article-title":"Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis","volume":"58","author":"Ramwadhdoebe","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104042_bb0645","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/art.40168","article-title":"Emerging treatment models in rheumatology: IgG4-related disease: insights into human immunology and targeted therapies","volume":"69","author":"Perugino","year":"2017","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104042_bb0650","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-025-01769-0","article-title":"Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases","volume":"19","author":"Chen","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.autrev.2026.104042_bb0655","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41573-024-00959-8","article-title":"Sequential immunotherapy: towards cures for autoimmunity","volume":"23","author":"Ram\u00edrez-Valle","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2026.104042_bb0660","doi-asserted-by":"crossref","first-page":"925","DOI":"10.15252\/embj.201489732","article-title":"CD19 and BAFF-R can signal to promote B-cell survival in the absence of Syk","volume":"34","author":"Hobeika","year":"2015","journal-title":"EMBO J"},{"key":"10.1016\/j.autrev.2026.104042_bb0665","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.autrev.2026.104042_bb0670","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1182\/blood-2004-11-4284","article-title":"Identification and characterization of circulating human transitional B cells","volume":"105","author":"Sims","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2026.104042_bb0675","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nri844","article-title":"BAFF: a fundamental survival factor for B cells","volume":"2","author":"Mackay","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0680","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9518137","article-title":"Peripheral B cell subsets in autoimmune diseases: clinical implications and effects of B cell-targeted therapies","volume":"2020","author":"Jin","year":"2020","journal-title":"J Immunol Res"},{"key":"10.1016\/j.autrev.2026.104042_bb0685","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.immuni.2020.11.006","article-title":"Germinal Center and extrafollicular B cell responses in vaccination, immunity, and autoimmunity","volume":"53","author":"Elsner","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2026.104042_bb0690","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41423-025-01377-5","article-title":"The multilayered identity of B cell memory","volume":"23","author":"Glaros","year":"2026","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.autrev.2026.104042_bb0695","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.autrev.2026.104042_bb0700","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/ard.2007.080960","article-title":"Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response","volume":"67","author":"Thurlings","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104042_bb0705","doi-asserted-by":"crossref","first-page":"R172","DOI":"10.1186\/ar4359","article-title":"Efficacy and safety of rituximab treatment in early primary Sj\u00f6gren\u2019s syndrome: a prospective, multi-center, follow-up study","volume":"15","author":"Carubbi","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104042_bb0710","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2007.079418","article-title":"B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response","volume":"67","author":"Cambridge","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104042_bb0715","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1474-4422(24)00140-6","article-title":"B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases","volume":"23","author":"Haghikia","year":"2024","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104042_bb0720","doi-asserted-by":"crossref","first-page":"eaeb6424","DOI":"10.1126\/sciadv.aeb6424","article-title":"BCMA\/CD19 CAR T cell therapy for refractory myasthenia gravis: proteomic signatures and single-cell transcriptomics of disease flares","volume":"12","author":"Huang","year":"2026","journal-title":"Sci Adv"},{"key":"10.1016\/j.autrev.2026.104042_bb0725","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.kint.2019.12.025","article-title":"Anti-CD20\u2013mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives","volume":"97","author":"Crickx","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2026.104042_bb0730","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.autrev.2010.05.006","article-title":"B-cell tolerance breakdown in Sj\u00f6gren\u2019s syndrome: focus on BAFF","volume":"9","author":"Varin","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104042_bb0735","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/ndt\/gfaa117","article-title":"Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results","volume":"36","author":"Kraaij","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2026.104042_bb0740","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaut.2018.03.003","article-title":"The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus","volume":"91","author":"Kraaij","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104042_bb0745","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41584-025-01343-5","article-title":"The dawn of \u2018off-the-shelf\u2019 B cell-depleting therapies for autoimmune diseases","volume":"22","author":"Xu","year":"2026","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2026.104042_bb0750","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ard.2025.10.010","article-title":"Low-dose belimumab reduced risk of flares in patients with systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"85","author":"Sun","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104042_bb0755","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1016\/S2665-9913(24)00162-0","article-title":"Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials","volume":"6","author":"Parodis","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2026.104042_bb0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103837","article-title":"Dual B-cell targeting in systemic lupus erythematosus: the role of combined and sequential therapy with rituximab and belimumab","volume":"24","author":"Frade-Sosa","year":"2025","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104042_bb0765","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-032569","article-title":"Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial","volume":"9","author":"Jones","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.autrev.2026.104042_bb0770","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.7326\/M21-2078","article-title":"Effectiveness of belimumab after rituximab in systemic lupus erythematosus","volume":"174","author":"Shipa","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2026.104042_bb0775","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/ard-2024-225686","article-title":"Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study","volume":"83","author":"Aranow","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104042_bb0780","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1177\/0961203320965707","article-title":"Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy","volume":"30","author":"Bela","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2026.104042_bb0785","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13063-023-07218-y","article-title":"A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol","volume":"24","author":"McClure","year":"2023","journal-title":"Trials"},{"key":"10.1016\/j.autrev.2026.104042_bb0790","first-page":"490","article-title":"Sequential therapy with belimumab followed by rituximab in Sj\u00f6gren\u2019s syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy","volume":"32","author":"De Vita","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl. 118","key":"10.1016\/j.autrev.2026.104042_bb0795","first-page":"199","article-title":"Double anti-B cell and anti-BAFF targeting for the treatment of primary Sj\u00f6gren\u2019s syndrome","volume":"37","author":"Gandolfo","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2026.104042_bb0800","doi-asserted-by":"crossref","first-page":"e830","DOI":"10.1016\/S2665-9913(25)00256-5","article-title":"Revisiting safety and refining benefit of rituximab\u2013belimumab combination for refractory SLE","volume":"7","author":"Ehrenstein","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2026.104042_bb0805","article-title":"IgA2+ B cells and IgA2 anti-dsDNA antibodies are selectively targeted by belimumab after rituximab therapy in systemic lupus erythematosus","volume":"6","author":"McCluskey","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.autrev.2026.104042_bb0810","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104042_bb0815","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001424","article-title":"Long-term safety and efficacy of the combination of belimumab and rituximab in the treatment of severe and refractory SLE: a preliminary report","volume":"12","author":"Van Schaik","year":"2025","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2026.104042_bb0820","first-page":"9","article-title":"Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE","author":"Struemper","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2026.104042_bb0825","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2013.12.002","article-title":"The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment","volume":"50","author":"Cambridge","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104042_bb0830","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ard.2025.06.2132","article-title":"Differential molecular signatures in response to CD19-CAR T cell therapy compared with conventional pharmacotherapy in systemic lupus erythematosus","volume":"85","author":"Garantziotis","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104042_bb0835","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.ard.2025.06.2120","article-title":"Effects of different B-cell-depleting strategies on the lymphatic tissue","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104042_bb0840","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13075-020-02177-0","article-title":"The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis","volume":"22","author":"Wilkinson","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104042_bb0845","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13075-015-0750-y","article-title":"Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sj\u00f6gren\u2019s syndrome: results of the BELISS study","volume":"17","author":"Seror","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104042_bb0850","doi-asserted-by":"crossref","first-page":"R167","DOI":"10.1186\/ar2076","article-title":"Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"8","author":"Vallerskog","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104042_bb0855","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2665-9913(22)00332-0","article-title":"Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial","volume":"5","author":"Shipa","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2026.104042_bb0860","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response","volume":"71","author":"van Vollenhoven","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104042_bb0865","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122525","article-title":"Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients","volume":"3","author":"Huang","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.autrev.2026.104042_bb0870","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2015-207654","volume":"75","author":"Merrill","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104042_bb0875","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/annrheumdis-2014-207090","article-title":"Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study","volume":"74","author":"Smolen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104042_bb0880","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s13075-015-0741-z","article-title":"Treatment of systemic lupus erythematosus patients with the BAFF antagonist \u201cpeptibody\u201d blisibimod (AMG 623\/A-623): results from randomized, double-blind phase 1a and phase 1b trials","volume":"17","author":"Stohl","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104042_bb0885","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/1756285610371146","article-title":"Atacicept: targeting B cells in multiple sclerosis","volume":"3","author":"Hartung","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.autrev.2026.104042_bb0890","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13075-025-03584-x","article-title":"Prospective analysis of B cell subset dynamics following telitacicept treatment in systemic lupus erythematosus","volume":"27","author":"Chen","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104042_bb0895","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-026-01779-6","article-title":"BCMA-CD19 armored compound CAR T cells in systemic lupus erythematosus: extended follow-up of a phase 1 clinical trial","volume":"19","author":"Hong","year":"2026","journal-title":"J Hematol Oncol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722600056X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722600056X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:13:58Z","timestamp":1778620438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156899722600056X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":179,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S156899722600056X"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104042","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The BAFF\/APRIL system at the crossroads of B cell memory and autoimmune relapse: Implication into the therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104042"}}